Compare IDEXX Laboratories, Inc. (IDXX) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs J M Smucker Co — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while J M Smucker Co trades at $117.46 (market cap $12.54B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.7× J M Smucker Co's market cap, and J M Smucker Co pays a 3.82% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | SJM | |
|---|---|---|
Market Cap | $46.22B | $12.54B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $126.35 |
52-Week Low | $526.44 | $89.53 |
Enterprise Value | $47.12B | $19.57B |
Dividend Yield | — | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
SJM trades at $118.84, up 0.65% today, with a bullish technical signal and support near $117. The company reported revenue of $8.73B in 2025 but a net loss of -$1.23B, though recent quarters show earnings beats. Analyst consensus is a Buy with a $125.11 price target, and the dividend was recently increased to $1.12 per share, marking 25 consecutive years of growth.
Outlook is mixed: strong cash flow and dividend growth support income investors, but negative margins and high debt pose risks. Upside depends on cost controls and Uncrustables growth offsetting sales declines. The stock offers value at a P/E of 22.05 but faces execution challenges in a competitive consumer staples market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
